ArticleAnnals of internal medicine2021
In high-risk adults, the Moderna vaccine had 94% efficacy against COVID-19 ≥14 d after the 2nd dose.
Article in Annals of internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Spike of SARS-CoV-2: Uniqueness and Applications.Frontiers in immunology · 2021Pooled it
- Prevalence and characteristics of post-acute sequelae of COVID-19 in recovered patients.Frontiers in public health · 2025Article
- Lessons we learned during the past four challenging years in the COVID-19 era: pharmacotherapy, long COVID complications, and vaccine development.Virology journal · 2024Review
- SARS-CoV-2 mRNA vaccination induces an intranasal mucosal response characterized by neutralizing antibodies.The journal of allergy and clinical immunology. Global · 2023Article
- Kinetics of adaptive immune responses after administering mRNA-Based COVID-19 vaccination in individuals with and without prior SARS-CoV-2 infections.BMC infectious diseases · 2023Article
- Immune Thrombocytopenia Relapse in Patients Who Received mRNA COVID-19 Vaccines.Journal of blood medicine · 2023Article
- Long COVID in the context of social determinants of health.Frontiers in public health · 2023Article
- Reduction in COVID-19 Vaccine Effectiveness against SARS-CoV-2 Variants in Seoul according to Age, Sex, and Symptoms: A Test-Negative Case-Control Study.International journal of environmental research and public health · 2022Article
- Efficacy versus abundancy: Comparing vaccination schemes.PloS one · 2022Article
- A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines.International immunopharmacology · 2021Review
- Proposals to Accelerate Novel Vaccine Development for Children.Pediatrics · 2021Article
- Could live attenuated vaccines better control COVID-19?Vaccine · 2021Review
- Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors.Nature communications · 2021Article
- Chitosan Nanoparticles for Antiviral Drug Delivery: A Novel Route for COVID-19 Treatment.International journal of nanomedicine · 2021Review
- Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.Frontiers in immunology · 2021Review
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
source citationBaden LR, El Sahly HM, Essink B, et al.
Indexed as
Identifiers
33646836What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.